• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

$25 in the future





Prove me wrong.
Nothing to prove wrong. Pipeline is weak and too much debt to buy our way into new products. Frank and Ian were all in for change, however; Albert must have some real dark dirt for them to put their tales between their legs and reverse course a few days later. Still not certain AB is safe. Starboard probably working institutions to push for change. We shall see I guess.
 




Nothing to prove wrong. Pipeline is weak and too much debt to buy our way into new products. Frank and Ian were all in for change, however; Albert must have some real dark dirt for them to put their tales between their legs and reverse course a few days later. Still not certain AB is safe. Starboard probably working institutions to push for change. We shall see I guess.
Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest…
Source: Reuters